{"id":5938,"date":"2021-12-11T20:08:30","date_gmt":"2021-12-11T20:08:30","guid":{"rendered":"https:\/\/maat.swebwp.oci.eu\/?p=5938"},"modified":"2023-09-25T13:54:17","modified_gmt":"2023-09-25T13:54:17","slug":"maat-pharma-presente-a-loccasion-de-la-63eme-rencontre-annuelle-de-lash-des-resultats-cliniques-prometteurs-issus-de-76-patients-atteints-de-la-maladie-du-greffon-contre-l","status":"publish","type":"post","link":"https:\/\/maat.swebwp.oci.eu\/fr\/maat-pharma-presente-a-loccasion-de-la-63eme-rencontre-annuelle-de-lash-des-resultats-cliniques-prometteurs-issus-de-76-patients-atteints-de-la-maladie-du-greffon-contre-l\/","title":{"rendered":"MaaT Pharma pr\u00e9sente, \u00e0 l\u2019occasion de la 63\u00e8me rencontre annuelle de l\u2019ASH, des r\u00e9sultats cliniques prometteurs issus de 76 patients atteints de la maladie du greffon contre l\u2019h\u00f4te aig\u00fce  trait\u00e9s avec MaaT013"},"content":{"rendered":"[vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/6&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb2\/3&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][vc_column_text]\n<h3 style=\"text-align: center;\"><strong>MaaT Pharma pr\u00e9sente, \u00e0 l\u2019occasion de la 63<sup>\u00e8me<\/sup> rencontre annuelle de l\u2019ASH, des r\u00e9sultats cliniques prometteurs issus de 76 patients atteints de la maladie du greffon contre l\u2019h\u00f4te aig\u00fce trait\u00e9s avec MaaT013<\/strong><\/h3>\n[\/vc_column_text]<div class=\"nectar-fancy-ul\" data-list-icon=\"icon-salient-thin-line\" data-animation=\"false\" data-animation-delay=\"0\" data-color=\"accent-color\" data-spacing=\"default\" data-alignment=\"left\"> \n<ul>\n<li>La pr\u00e9sentation orale, donn\u00e9e \u00e0 l\u2019occasion de la <a href=\"https:\/\/www.hematology.org\/meetings\/annual-meeting\">rencontre annuelle de l\u2019American Society of Hematology (ASH),<\/a> porte sur les r\u00e9sultats de l\u2019essai clinique HERACLES de Phase 2 chez 24 patients atteints de la maladie du greffon contre l\u2019h\u00f4te aig\u00fce (aGvH) \u00e0 pr\u00e9dominance gastrointestinale (GI) de grade III-IV et r\u00e9fractaires aux st\u00e9ro\u00efdes et sur les donn\u00e9es issues du programme d\u2019acc\u00e8s compassionnel (EAP) pour MaaT013 en France chez 52 patients avec une aGvH GI de grade II-IV, pour lesquels les traitements pr\u00e9c\u00e9dents avaient \u00e9chou\u00e9<\/li>\n<li>Le taux de r\u00e9ponse globale GI (GI-ORR) \u00e0 MaaT013 au jour 28 \u00e9tait de 38% dans l\u2019essai HERACLES, dont 5 patients en r\u00e9ponse compl\u00e8te (21%)\u00a0et de 58% en EAP, dont 17 patients en r\u00e9ponse compl\u00e8te (33%)<\/li>\n<li>Le meilleur GI-ORR au jour 28 \u00e9tait de 54% dans HERACLES et 67% dans l\u2019EAP<\/li>\n<li>Le taux de survie \u00e0 12 mois pour les patients r\u00e9pondeurs au traitement \u00e9tait de 44% pour HERACLES et 59% pour l\u2019EAP<\/li>\n<li>Une \u00e9tude clinique pivot de Phase 3 de MaaT013 en aGvH est en cours d\u2019initiation<\/li>\n<\/ul>\n <\/div>[vc_column_text]\n<p style=\"text-align: center;\"><strong>MaaT Pharma organisera un webcast pour les investisseurs le lundi 13 d\u00e9cembre \u00e0 18h00 CET :<\/strong><\/p>\n<p>Afin de pr\u00e9senter les donn\u00e9es cliniques du programme MaaT013 et r\u00e9aliser un point d\u2019\u00e9tape sur l\u2019entreprise,<strong> MaaT Pharma organisera un webcast pour les investisseurs le lundi 13 d\u00e9cembre 2021 \u00e0 18h00 CET<\/strong> <strong>\/12h00 EST<\/strong>.\u00a0 <strong>Pour vous inscrire et acc\u00e9der au webcast, <\/strong><a href=\"https:\/\/onlinexperiences.com\/Launch\/QReg\/ShowUUID=E9359D2D-D865-4920-BEF0-51147F5CD975&amp;LangLocaleID=1036\"><strong>veuillez cliquer ici<\/strong><\/a><strong>.<\/strong> Une rediffusion sera disponible peu apr\u00e8s la fin du webcast et archiv\u00e9e sur le site internet de MaaT Pharma pendant au moins 90 jours.<\/p>\n<p>&nbsp;<\/p>\n[\/vc_column_text][vc_column_text]<strong>Lyon, France, 11 d\u00e9cembre, 2021 &#8211; 21h00 CET\u2013<\/strong> <strong>MaaT Pharma S.A. (<\/strong>\u00ab <strong>MaaT Pharma <\/strong>\u00bb<strong> ou la <\/strong>\u00ab <strong>Soci\u00e9t\u00e9 <\/strong>\u00bb<strong>), soci\u00e9t\u00e9 fran\u00e7aise de biotechnologies en stade clinique avanc\u00e9, pionni\u00e8re dans le d\u00e9veloppement de m\u00e9dicaments dans la restauration du microbiote intestinal pour am\u00e9liorer la survie des patients atteints de cancers,<\/strong> annonce aujourd\u2019hui des r\u00e9sultats compl\u00e9mentaires issus de la Phase 2 de l\u2019essai clinique HERACLES (<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03359980\">NCT03359980<\/a>) et du programme d\u2019acc\u00e8s compassionnel en France pour MaaT013, <em>Microbiome Ecosystem Therapy<\/em><a href=\"#_ftn1\" name=\"_ftnref1\"><sup>[1]<\/sup><\/a> (MET) \u00e0 haute richesse et haute diversit\u00e9 microbienne, produit le plus avanc\u00e9 de son portefeuille. Les donn\u00e9es montrent que le traitement par MaaT013 de patients ayant d\u00e9velopp\u00e9 une maladie aig\u00fce du greffon contre l&rsquo;h\u00f4te avec atteinte gastro-intestinale (GI-aGvH) \u00e0 la suite d\u2019une transplantation de cellules souches h\u00e9matopo\u00ef\u00e9tiques pr\u00e9sentait un taux de r\u00e9ponse gastro-intestinale globale (GI-ORR)<a href=\"#_ftn2\" name=\"_ftnref2\"><sup>[2]<\/sup><\/a> prometteur dans les deux groupes. Le crit\u00e8re d\u2019\u00e9valuation principal GI-ORR au jour 28 \u00e9tait de 38% dans l\u2019essai HERACLES et 58% chez les patients EAP, respectivement. Le crit\u00e8re d\u2019\u00e9valuation secondaire de meilleure r\u00e9ponse GI (Best GI-ORR) dans les 28 jours \u00e9tait de 54% pour l\u2019essai HERACLES et de 67% pour l\u2019EAP. Le b\u00e9n\u00e9fice clinique observ\u00e9 avec l&rsquo;administration de MaaT013 a eu un impact positif sur les taux de survie globale (OS) des patients qui ont r\u00e9pondu au traitement : OS \u00e0 12 mois chez les r\u00e9pondeurs de 44% chez les patients HERACLES et 59% chez les patients EAP. MaaT013 a \u00e9galement \u00e9t\u00e9 bien tol\u00e9r\u00e9 au sein de cette population de patients fortement immunod\u00e9prim\u00e9s.<\/p>\n<p>Les donn\u00e9es ont \u00e9t\u00e9 partag\u00e9es lors d\u2019une pr\u00e9sentation orale tenue par le <strong>docteur Florent Malard<\/strong>, <strong>H\u00e9matologue \u00e0 l\u2019H\u00f4pital Saint-Antoine et professeur agr\u00e9g\u00e9 \u00e0 Sorbonne Universit\u00e9<\/strong>, Paris -France le samedi 11 d\u00e9cembre \u00e0 20h45 CET \/ 14h45 EST \u2013\u00e0 l\u2019occasion de la <a href=\"https:\/\/www.hematology.org\/meetings\/annual-meeting\">63<sup>\u00e8me<\/sup> rencontre annuelle de l\u2019ASH. <\/a><\/p>\n<p><em>\u00ab\u00a0Les r\u00e9sultats cliniques positifs obtenus \u00e0 la suite du traitement par MaaT013 sont tr\u00e8s encourageants. MaaT013 continue de se montrer prometteur en tant qu&rsquo;option th\u00e9rapeutique pour les patients atteints de GvH aigu\u00eb, une maladie d\u00e9vastatrice dont la survie \u00e0 long terme est tr\u00e8s faible en cas d&rsquo;\u00e9chec de l&rsquo;administration de st\u00e9ro\u00efdes\u00a0\u00bb, <\/em>a d\u00e9clar\u00e9 le <strong>Pr Mohamad Mohty, Professeur d\u2019h\u00e9matologie \u00e0 Sorbonne Universit\u00e9 et Chef du service d&rsquo;H\u00e9matologie Clinique et Th\u00e9rapie Cellulaire \u00e0 l\u2019H\u00f4pital Saint-Antoine.<\/strong><em> \u00ab\u00a0Le taux de survie observ\u00e9 chez les patients trait\u00e9s avec MaaT013 est tr\u00e8s encourageant, tant dans l&rsquo;essai clinique de Phase 2 chez des patients avec des atteintes tr\u00e8s s\u00e9v\u00e8res que dans le programme d\u2019acc\u00e8s compassionnel, et met en lumi\u00e8re l\u2019effet positif jou\u00e9 par MaaT013. \u00bb <\/em><\/p>\n<p><em>\u00ab\u00a0Ces donn\u00e9es soutiennent fortement notre hypoth\u00e8se, selon laquelle la restauration de la diversit\u00e9 du microbiote intestinal peut avoir un impact significatif sur la survie des patients atteints d\u2019aGvH. Ces r\u00e9sultats nous rapprochent de plus en plus de la possibilit\u00e9 de proposer MaaT013 \u00e0 des patients qui aujourd\u2019hui n\u2019ont pas d\u2019autre option de traitement\u00a0\u00bb, <\/em>a ajout\u00e9 le <strong>docteur<\/strong> <strong>John Weinberg, directeur m\u00e9dical de MaaT Pharma<\/strong>.<em> \u00ab\u00a0Sur la base du b\u00e9n\u00e9fice clinique observ\u00e9 aupr\u00e8s de 76 patients atteints de cette maladie rare, nous sommes impatients de lancer une \u00e9tude pivot de Phase 3 avec MaaT013 comme traitement de troisi\u00e8me ligne chez les patients atteints de GI-aGvH. \u00c0 ce jour, nous avons re\u00e7u un retour positif de deux agences r\u00e9glementaires europ\u00e9ennes et nous communiquerons lors de l\u2019inclusion de notre premier patient.\u00a0\u00bb<\/em><\/p>\n<p><strong><br \/>\nPrincipaux r\u00e9sultats cliniques de MaaT013 dans l&rsquo;\u00e9tude de Phase 2 HERACLES<\/strong><\/p>\n<p><em>Dans l&rsquo;\u00e9tude HERACLES, 24 patients atteints d\u2019une aGvH gastro-intestinale de grade III-IV r\u00e9fractaire aux st\u00e9ro\u00efdes ont \u00e9t\u00e9 trait\u00e9s avec MaaT013 en tant que traitement de seconde ligne.<\/em><\/p>\n<ul>\n<li>9 patients sur 24 (38%) ont pr\u00e9sent\u00e9 une r\u00e9ponse GI objective au 28<sup>\u00e8me<\/sup> jour, dont 5 patients (21%) ont pr\u00e9sent\u00e9 une r\u00e9ponse compl\u00e8te, 2 patients (8%) une tr\u00e8s bonne r\u00e9ponse partielle et 2 patients (8%) une r\u00e9ponse partielle.<\/li>\n<li>La meilleure r\u00e9ponse GI (Best GI-ORR) au 28<sup>\u00e8me<\/sup> jour \u00e9tait de 54% (13 patients), dont 38% (9 patients) en r\u00e9ponse compl\u00e8te.<\/li>\n<li>Le taux de survie globale (OS) \u00e0 12 mois des patients r\u00e9pondeurs au traitement \u00e9tait de 44%, contre 13% chez les non-r\u00e9pondeurs (la survie globale chez tous les patients inclus \u00e9tait de 25% \u00e0 12 mois).<\/li>\n<li>Le traitement par MaaT013 a \u00e9t\u00e9 bien tol\u00e9r\u00e9, la majorit\u00e9 des \u00e9v\u00e9nements ind\u00e9sirables survenus pendant le traitement (TEAE) \u00e9tant des infections et des troubles gastro-intestinaux, attendus chez les patients atteints de GvH.<\/li>\n<li>Chez les patients r\u00e9pondeurs, le traitement par MaaT013 a augment\u00e9 de mani\u00e8re significative l&rsquo;alpha-diversit\u00e9, c\u2019est-\u00e0-dire le nombre d\u2019esp\u00e8ces bact\u00e9riennes diff\u00e9rentes dans le microbiote, et ce d\u00e8s la premi\u00e8re dose.<\/li>\n<\/ul>\n<p><strong><br \/>\n<\/strong><strong>Principaux r\u00e9sultats cliniques obtenus avec MaaT013 dans le cadre du programme d&rsquo;acc\u00e8s compassionnel en France (\u00ab\u00a0Early Access Program\u00a0\u00bb &#8211; EAP) <\/strong><\/p>\n<p><em>Dans le cadre de l&rsquo;EAP, 52 patients pr\u00e9sentant une aGvH gastro-intestinale de grade II-IV, d\u00e9pendante ou r\u00e9sistante aux st\u00e9ro\u00efdes, ont \u00e9t\u00e9 trait\u00e9s avec MaaT013.<\/em><\/p>\n<ul>\n<li>30 des 52 patients (58%) ont pr\u00e9sent\u00e9 une r\u00e9ponse GI objective, dont 17 patients (33%) ont pr\u00e9sent\u00e9 une r\u00e9ponse compl\u00e8te, 9 patients (17%) une tr\u00e8s bonne r\u00e9ponse partielle et 4 patients (8%) une r\u00e9ponse partielle.<\/li>\n<li>La meilleure r\u00e9ponse GI (Best GI-ORR) au 28<sup>\u00e8me<\/sup> jour \u00e9tait de 67% (35 patients), dont 40% (21 patients) en r\u00e9ponse compl\u00e8te.<\/li>\n<li>Le taux de survie globale (OS) \u00e0 12 mois des patients r\u00e9pondeurs au traitement \u00e9tait de 59%, contre 7% chez les non-r\u00e9pondeurs (la survie globale chez tous les patients inclus \u00e9tait de 38% \u00e0 12 mois).<\/li>\n<li>Au moment du traitement, tous les patients pr\u00e9sentaient une aGvH de grade II (6%) ou de grade III (94%).<\/li>\n<li>Les patients ont re\u00e7u MaaT013 apr\u00e8s 1 \u00e0 6 lignes de traitement (m\u00e9diane : 3). 43 des 52 patients (83%) \u00e9taient r\u00e9sistants aux st\u00e9ro\u00efdes et 40 des 52 (77%) n&rsquo;avaient pas r\u00e9pondu au ruxolitinib.<\/li>\n<\/ul>\n<h6><a href=\"#_ftnref1\" name=\"_ftn1\">[1]<\/a> Th\u00e9rapie microbiote \u00e0 \u00e9cosyst\u00e8me complet<\/h6>\n<h6><a href=\"#_ftnref2\" name=\"_ftn2\">[2]<\/a> L\u2019ORR inclut la r\u00e9ponse compl\u00e8te (CR), tr\u00e8s bonne r\u00e9ponse partielle (VGPR) et la r\u00e9ponse partielle (PR)<\/h6>\n[\/vc_column_text][\/vc_column][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/6&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column][\/vc_row][vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/6&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb2\/3&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][vc_column_text]<strong>A propos de MaaT013<\/strong><\/p>\n<p>MaaT013 est une Microbiome Ecosystem Therapy (microbioth\u00e9rapie \u00e0 \u00e9cosyst\u00e8me complet) pr\u00eate \u00e0 l\u2019emploi, standardis\u00e9e et issue d\u2019une combinaison de microbiotes de donneurs sains. Le produit est caract\u00e9ris\u00e9 par une diversit\u00e9 et une richesse \u00e9lev\u00e9es et standardis\u00e9es des esp\u00e8ces microbiennes qu\u2019il contient et la pr\u00e9sence de Butycore<sup>TM<\/sup> (ensemble de bact\u00e9ries produisant des m\u00e9tabolites anti-inflammatoires). MaaT013 a pour but de restaurer la relation symbiotique entre le microbiote intestinal du patient et son syst\u00e8me immunitaire, afin de corriger la r\u00e9activit\u00e9 et restaurer la tol\u00e9rance des fonctions immunitaires et ainsi de r\u00e9duire l\u2019aGvH gastro-intestinale r\u00e9sistante aux st\u00e9ro\u00efdes. MaaT013 a re\u00e7u la d\u00e9signation de m\u00e9dicament orphelin de la Food and Drug Administration (FDA) aux \u00c9tats-Unis et de l&rsquo;Agence europ\u00e9enne des m\u00e9dicaments (EMA). MaaT013 a \u00e9t\u00e9 \u00e9valu\u00e9 dans un essai clinique de Phase 2 (HERACLES, <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03359980\">NCT03359980<\/a>) et est administr\u00e9 dans le cadre d\u2019une autorisation d\u2019acc\u00e8s compassionnel en France.[\/vc_column_text][\/vc_column][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/6&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column][\/vc_row][vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/6&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb2\/3&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][vc_column_text]<strong>A propos de MaaT Pharma<\/strong><\/p>\n<p>MaaT Pharma est une soci\u00e9t\u00e9 de biotechnologies au stade clinique qui a mis au point une approche compl\u00e8te pour restaurer la symbiose microbiote\/h\u00f4te des patients atteints de cancers. Engag\u00e9e dans le traitement des cancers et de la maladie du greffon contre l\u2019h\u00f4te (GVH), une complication grave survenant apr\u00e8s une greffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques, MaaT Pharma a d\u00e9j\u00e0 r\u00e9alis\u00e9 la preuve de concept de son approche chez des patients atteints de GVH aigu\u00eb dans un essai clinique de Phase 2. Notre puissante plateforme de d\u00e9couverte et d\u2019analyse, gutPrint\u00ae, soutient le d\u00e9veloppement de notre portefeuille de produits et son extension \u00e0 des indications plus larges en aidant \u00e0 d\u00e9terminer de nouvelles cibles th\u00e9rapeutiques, \u00e0 \u00e9valuer les m\u00e9dicaments candidats et \u00e0 identifier des biomarqueurs pour la prise en charge de pathologies impliquant le microbiote.<\/p>\n<p>Les th\u00e9rapies issues d\u2019un \u00e9cosyst\u00e8me microbien (<em>Microbiome Ecosystem Therapies<\/em>) sont toutes produites dans le cadre tr\u00e8s standardis\u00e9 d\u2019une fabrication et de contr\u00f4les qualit\u00e9 cGMP afin de garantir en toute s\u00e9curit\u00e9 l\u2019acc\u00e8s \u00e0 la diversit\u00e9 et la richesse du microbiome, sous forme orale ou d\u2019enema. MaaT Pharma b\u00e9n\u00e9ficie de l\u2019engagement de scientifiques de renomm\u00e9e mondiale et de relations \u00e9tablies avec les instances r\u00e9glementaires pour faire progresser l\u2019int\u00e9gration des th\u00e9rapies \u00e0 base de microbiote dans la pratique clinique.<\/p>\n<p>MaaT Pharma est cot\u00e9e sur Euronext Paris (Code mn\u00e9monique\u00a0: MAAT).[\/vc_column_text][vc_column_text]<strong>Donn\u00e9es prospectives <\/strong><\/p>\n<p>Ce communiqu\u00e9 de presse contient des d\u00e9clarations prospectives. Toutes les d\u00e9clarations autres que les \u00e9nonc\u00e9s de faits historiques inclus dans le pr\u00e9sent communiqu\u00e9 de presse au sujet d&rsquo;\u00e9v\u00e9nements futurs sont sujettes \u00e0 (i) des changements sans pr\u00e9avis et (ii) des facteurs ind\u00e9pendants de la volont\u00e9 de la Soci\u00e9t\u00e9. Ces d\u00e9clarations peuvent comprendre, sans s&rsquo;y limiter, tout \u00e9nonc\u00e9 pr\u00e9c\u00e9d\u00e9, suivi ou incluant des mots tels que \u00ab cibler \u00bb, \u00ab croire \u00bb, \u00ab s&rsquo;attendre \u00e0 \u00bb, \u00ab viser \u00bb, \u00ab avoir l&rsquo;intention de \u00bb, \u00ab pouvoir \u00bb, \u00ab pr\u00e9voir \u00bb, \u00ab estimer \u00bb, \u00ab planifier \u00bb, \u00ab projeter \u00bb, \u00ab vouloir \u00bb, \u00ab pouvoir avoir \u00bb, \u00ab susceptible de \u00bb, \u00ab probable \u00bb, \u00ab devoir \u00bb, \u00ab pr\u00e9visions \u00bb et d\u2019autres mots et termes ayant un sens similaire ou la forme n\u00e9gative qui en d\u00e9coule. Les d\u00e9clarations prospectives sont assujetties \u00e0 des risques et \u00e0 des incertitudes inh\u00e9rentes ind\u00e9pendants de la volont\u00e9 de la Soci\u00e9t\u00e9 qui pourraient conduire \u00e0 ce que les r\u00e9sultats ou les performances r\u00e9els de la Soci\u00e9t\u00e9 diff\u00e8rent consid\u00e9rablement des r\u00e9sultats ou des performances attendus exprim\u00e9s ou sous-entendus dans ces d\u00e9clarations prospectives.[\/vc_column_text][\/vc_column][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/6&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][divider line_type=\u00a0\u00bbNo Line\u00a0\u00bb][divider line_type=\u00a0\u00bbNo Line\u00a0\u00bb][divider line_type=\u00a0\u00bbNo Line\u00a0\u00bb][divider line_type=\u00a0\u00bbNo Line\u00a0\u00bb][divider line_type=\u00a0\u00bbNo Line\u00a0\u00bb][divider line_type=\u00a0\u00bbNo Line\u00a0\u00bb][divider line_type=\u00a0\u00bbNo Line\u00a0\u00bb][divider line_type=\u00a0\u00bbNo Line\u00a0\u00bb][divider line_type=\u00a0\u00bbNo Line\u00a0\u00bb][divider line_type=\u00a0\u00bbNo Line\u00a0\u00bb][divider line_type=\u00a0\u00bbNo Line\u00a0\u00bb][divider line_type=\u00a0\u00bbNo Line\u00a0\u00bb][divider line_type=\u00a0\u00bbNo Line\u00a0\u00bb][divider line_type=\u00a0\u00bbNo Line\u00a0\u00bb][divider line_type=\u00a0\u00bbNo Line\u00a0\u00bb][divider line_type=\u00a0\u00bbNo Line\u00a0\u00bb][divider line_type=\u00a0\u00bbNo Line\u00a0\u00bb][divider line_type=\u00a0\u00bbNo Line\u00a0\u00bb][divider line_type=\u00a0\u00bbNo Line\u00a0\u00bb][divider line_type=\u00a0\u00bbNo Line\u00a0\u00bb][divider line_type=\u00a0\u00bbNo Line\u00a0\u00bb][divider line_type=\u00a0\u00bbNo Line\u00a0\u00bb][divider line_type=\u00a0\u00bbNo Line\u00a0\u00bb][divider line_type=\u00a0\u00bbNo Line\u00a0\u00bb][divider line_type=\u00a0\u00bbNo Line\u00a0\u00bb][divider line_type=\u00a0\u00bbNo Line\u00a0\u00bb][image_with_animation image_url=\u00a0\u00bb5377&Prime; animation=\u00a0\u00bbFade In\u00a0\u00bb hover_animation=\u00a0\u00bbnone\u00a0\u00bb alignment=\u00a0\u00bb\u00a0\u00bb border_radius=\u00a0\u00bbnone\u00a0\u00bb box_shadow=\u00a0\u00bbnone\u00a0\u00bb image_loading=\u00a0\u00bbdefault\u00a0\u00bb max_width=\u00a0\u00bb100%\u00a0\u00bb max_width_mobile=\u00a0\u00bbdefault\u00a0\u00bb][\/vc_column][\/vc_row][vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/6&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb2\/3&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][nectar_btn size=\u00a0\u00bbsmall\u00a0\u00bb open_new_tab=\u00a0\u00bbtrue\u00a0\u00bb button_style=\u00a0\u00bbregular\u00a0\u00bb button_color_2=\u00a0\u00bbAccent-Color\u00a0\u00bb icon_family=\u00a0\u00bbnone\u00a0\u00bb text=\u00a0\u00bbT\u00e9l\u00e9charger le communiqu\u00e9 de presse\u00a0\u00bb url=\u00a0\u00bbhttps:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/12\/211211_CP-MaaT013-ASH2021-Donnees_FR_VF.pdf\u00a0\u00bb][\/vc_column][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/6&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][\/vc_column][\/vc_row]\n","protected":false},"excerpt":{"rendered":"<p>[vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/6&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb&#8230;<\/p>\n","protected":false},"author":2,"featured_media":7120,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[21],"tags":[],"category_press":[],"year_press":[49],"class_list":{"0":"post-5938","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-communiques-de-presse-fr","8":"year_press-49"},"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.3.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>MaaT Pharma pr\u00e9sente, \u00e0 l\u2019occasion de la 63\u00e8me rencontre annuelle de l\u2019ASH, des r\u00e9sultats cliniques prometteurs issus de 76 patients atteints de la maladie du greffon contre l\u2019h\u00f4te aig\u00fce trait\u00e9s avec MaaT013 - MaaT Pharma<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MaaT Pharma pr\u00e9sente, \u00e0 l\u2019occasion de la 63\u00e8me rencontre annuelle de l\u2019ASH, des r\u00e9sultats cliniques prometteurs issus de 76 patients atteints de la maladie du greffon contre l\u2019h\u00f4te aig\u00fce trait\u00e9s avec MaaT013 - MaaT Pharma\" \/>\n<meta property=\"og:description\" content=\"[vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/6&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-presents-promising-clinical-data-from-76-patients-with-acute-graft-vs-host-disease-treated-with-maat013-at-63rd-ash-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"MaaT Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2021-12-11T20:08:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-09-25T13:54:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png\" \/>\n\t<meta property=\"og:image:width\" content=\"2362\" \/>\n\t<meta property=\"og:image:height\" content=\"2362\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"MaaT Pharma\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"MaaT Pharma\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-presents-promising-clinical-data-from-76-patients-with-acute-graft-vs-host-disease-treated-with-maat013-at-63rd-ash-annual-meeting\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-presents-promising-clinical-data-from-76-patients-with-acute-graft-vs-host-disease-treated-with-maat013-at-63rd-ash-annual-meeting\/\"},\"author\":{\"name\":\"MaaT Pharma\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34\"},\"headline\":\"MaaT Pharma pr\u00e9sente, \u00e0 l\u2019occasion de la 63\u00e8me rencontre annuelle de l\u2019ASH, des r\u00e9sultats cliniques prometteurs issus de 76 patients atteints de la maladie du greffon contre l\u2019h\u00f4te aig\u00fce trait\u00e9s avec MaaT013\",\"datePublished\":\"2021-12-11T20:08:30+00:00\",\"dateModified\":\"2023-09-25T13:54:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-presents-promising-clinical-data-from-76-patients-with-acute-graft-vs-host-disease-treated-with-maat013-at-63rd-ash-annual-meeting\/\"},\"wordCount\":3363,\"publisher\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#organization\"},\"image\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-presents-promising-clinical-data-from-76-patients-with-acute-graft-vs-host-disease-treated-with-maat013-at-63rd-ash-annual-meeting\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png\",\"articleSection\":[\"Communiqu\u00e9s de presse\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-presents-promising-clinical-data-from-76-patients-with-acute-graft-vs-host-disease-treated-with-maat013-at-63rd-ash-annual-meeting\/\",\"url\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-presents-promising-clinical-data-from-76-patients-with-acute-graft-vs-host-disease-treated-with-maat013-at-63rd-ash-annual-meeting\/\",\"name\":\"MaaT Pharma pr\u00e9sente, \u00e0 l\u2019occasion de la 63\u00e8me rencontre annuelle de l\u2019ASH, des r\u00e9sultats cliniques prometteurs issus de 76 patients atteints de la maladie du greffon contre l\u2019h\u00f4te aig\u00fce trait\u00e9s avec MaaT013 - MaaT Pharma\",\"isPartOf\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-presents-promising-clinical-data-from-76-patients-with-acute-graft-vs-host-disease-treated-with-maat013-at-63rd-ash-annual-meeting\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-presents-promising-clinical-data-from-76-patients-with-acute-graft-vs-host-disease-treated-with-maat013-at-63rd-ash-annual-meeting\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png\",\"datePublished\":\"2021-12-11T20:08:30+00:00\",\"dateModified\":\"2023-09-25T13:54:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-presents-promising-clinical-data-from-76-patients-with-acute-graft-vs-host-disease-treated-with-maat013-at-63rd-ash-annual-meeting\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-presents-promising-clinical-data-from-76-patients-with-acute-graft-vs-host-disease-treated-with-maat013-at-63rd-ash-annual-meeting\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-presents-promising-clinical-data-from-76-patients-with-acute-graft-vs-host-disease-treated-with-maat013-at-63rd-ash-annual-meeting\/#primaryimage\",\"url\":\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png\",\"contentUrl\":\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png\",\"width\":1080,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-presents-promising-clinical-data-from-76-patients-with-acute-graft-vs-host-disease-treated-with-maat013-at-63rd-ash-annual-meeting\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/maat.swebwp.oci.eu\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MaaT Pharma pr\u00e9sente, \u00e0 l\u2019occasion de la 63\u00e8me rencontre annuelle de l\u2019ASH, des r\u00e9sultats cliniques prometteurs issus de 76 patients atteints de la maladie du greffon contre l\u2019h\u00f4te aig\u00fce trait\u00e9s avec MaaT013\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#website\",\"url\":\"https:\/\/maat.swebwp.oci.eu\/\",\"name\":\"MaaT Pharma\",\"description\":\"microbiota gut to fight cancer\",\"publisher\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/maat.swebwp.oci.eu\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#organization\",\"name\":\"Maat Pharma\",\"url\":\"https:\/\/maat.swebwp.oci.eu\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png\",\"contentUrl\":\"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png\",\"width\":150,\"height\":171,\"caption\":\"Maat Pharma\"},\"image\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34\",\"name\":\"MaaT Pharma\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MaaT Pharma pr\u00e9sente, \u00e0 l\u2019occasion de la 63\u00e8me rencontre annuelle de l\u2019ASH, des r\u00e9sultats cliniques prometteurs issus de 76 patients atteints de la maladie du greffon contre l\u2019h\u00f4te aig\u00fce trait\u00e9s avec MaaT013 - MaaT Pharma","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"MaaT Pharma pr\u00e9sente, \u00e0 l\u2019occasion de la 63\u00e8me rencontre annuelle de l\u2019ASH, des r\u00e9sultats cliniques prometteurs issus de 76 patients atteints de la maladie du greffon contre l\u2019h\u00f4te aig\u00fce trait\u00e9s avec MaaT013 - MaaT Pharma","og_description":"[vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/6&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb...","og_url":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-presents-promising-clinical-data-from-76-patients-with-acute-graft-vs-host-disease-treated-with-maat013-at-63rd-ash-annual-meeting\/","og_site_name":"MaaT Pharma","article_published_time":"2021-12-11T20:08:30+00:00","article_modified_time":"2023-09-25T13:54:17+00:00","og_image":[{"width":2362,"height":2362,"url":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png","type":"image\/png"}],"author":"MaaT Pharma","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"MaaT Pharma","Dur\u00e9e de lecture estim\u00e9e":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-presents-promising-clinical-data-from-76-patients-with-acute-graft-vs-host-disease-treated-with-maat013-at-63rd-ash-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-presents-promising-clinical-data-from-76-patients-with-acute-graft-vs-host-disease-treated-with-maat013-at-63rd-ash-annual-meeting\/"},"author":{"name":"MaaT Pharma","@id":"https:\/\/maat.swebwp.oci.eu\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34"},"headline":"MaaT Pharma pr\u00e9sente, \u00e0 l\u2019occasion de la 63\u00e8me rencontre annuelle de l\u2019ASH, des r\u00e9sultats cliniques prometteurs issus de 76 patients atteints de la maladie du greffon contre l\u2019h\u00f4te aig\u00fce trait\u00e9s avec MaaT013","datePublished":"2021-12-11T20:08:30+00:00","dateModified":"2023-09-25T13:54:17+00:00","mainEntityOfPage":{"@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-presents-promising-clinical-data-from-76-patients-with-acute-graft-vs-host-disease-treated-with-maat013-at-63rd-ash-annual-meeting\/"},"wordCount":3363,"publisher":{"@id":"https:\/\/maat.swebwp.oci.eu\/#organization"},"image":{"@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-presents-promising-clinical-data-from-76-patients-with-acute-graft-vs-host-disease-treated-with-maat013-at-63rd-ash-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png","articleSection":["Communiqu\u00e9s de presse"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-presents-promising-clinical-data-from-76-patients-with-acute-graft-vs-host-disease-treated-with-maat013-at-63rd-ash-annual-meeting\/","url":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-presents-promising-clinical-data-from-76-patients-with-acute-graft-vs-host-disease-treated-with-maat013-at-63rd-ash-annual-meeting\/","name":"MaaT Pharma pr\u00e9sente, \u00e0 l\u2019occasion de la 63\u00e8me rencontre annuelle de l\u2019ASH, des r\u00e9sultats cliniques prometteurs issus de 76 patients atteints de la maladie du greffon contre l\u2019h\u00f4te aig\u00fce trait\u00e9s avec MaaT013 - MaaT Pharma","isPartOf":{"@id":"https:\/\/maat.swebwp.oci.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-presents-promising-clinical-data-from-76-patients-with-acute-graft-vs-host-disease-treated-with-maat013-at-63rd-ash-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-presents-promising-clinical-data-from-76-patients-with-acute-graft-vs-host-disease-treated-with-maat013-at-63rd-ash-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png","datePublished":"2021-12-11T20:08:30+00:00","dateModified":"2023-09-25T13:54:17+00:00","breadcrumb":{"@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-presents-promising-clinical-data-from-76-patients-with-acute-graft-vs-host-disease-treated-with-maat013-at-63rd-ash-annual-meeting\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/maat.swebwp.oci.eu\/maat-pharma-presents-promising-clinical-data-from-76-patients-with-acute-graft-vs-host-disease-treated-with-maat013-at-63rd-ash-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-presents-promising-clinical-data-from-76-patients-with-acute-graft-vs-host-disease-treated-with-maat013-at-63rd-ash-annual-meeting\/#primaryimage","url":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png","contentUrl":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png","width":1080,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-presents-promising-clinical-data-from-76-patients-with-acute-graft-vs-host-disease-treated-with-maat013-at-63rd-ash-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/maat.swebwp.oci.eu\/fr\/"},{"@type":"ListItem","position":2,"name":"MaaT Pharma pr\u00e9sente, \u00e0 l\u2019occasion de la 63\u00e8me rencontre annuelle de l\u2019ASH, des r\u00e9sultats cliniques prometteurs issus de 76 patients atteints de la maladie du greffon contre l\u2019h\u00f4te aig\u00fce trait\u00e9s avec MaaT013"}]},{"@type":"WebSite","@id":"https:\/\/maat.swebwp.oci.eu\/#website","url":"https:\/\/maat.swebwp.oci.eu\/","name":"MaaT Pharma","description":"microbiota gut to fight cancer","publisher":{"@id":"https:\/\/maat.swebwp.oci.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/maat.swebwp.oci.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/maat.swebwp.oci.eu\/#organization","name":"Maat Pharma","url":"https:\/\/maat.swebwp.oci.eu\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/maat.swebwp.oci.eu\/#\/schema\/logo\/image\/","url":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","contentUrl":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","width":150,"height":171,"caption":"Maat Pharma"},"image":{"@id":"https:\/\/maat.swebwp.oci.eu\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/maat.swebwp.oci.eu\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34","name":"MaaT Pharma"}]}},"_links":{"self":[{"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/posts\/5938","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/comments?post=5938"}],"version-history":[{"count":0,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/posts\/5938\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/media\/7120"}],"wp:attachment":[{"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/media?parent=5938"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/categories?post=5938"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/tags?post=5938"},{"taxonomy":"category_press","embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/category_press?post=5938"},{"taxonomy":"year_press","embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/year_press?post=5938"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}